Disease block
C73-C75 – Bösartige Neubildungen der Schilddrüse und sonstiger endokriner Drüsen
- Chapter II: Neubildungen
14Decisions
16Patient groups
Added benefit by patient group
- Major1
- Non-quantifiable2
- Not proven13
Diseases in this disease block
Decisions, newest first
Each decision lists only the patient groups coded with a disease in this disease block.
- 2025-11-20RetsevmoSelpercatinibMajor
- 2025-10-16AugtyroRepotrectinibNot proven: 2 of 2 patient groups
- 2024-11-07RetsevmoSelpercatinibNot proven
- 2024-11-07RetsevmoSelpercatinibNot proven: 2 of 2 patient groups
- 2024-02-06RozlytrekEntrectinibNot proven
- 2022-12-01Cabometyx CabozantinibNot proven
- 2022-03-18CaprelsaVandetanibNot proven
- 2021-12-16CometriqCabozantinibNon-quantifiable
- 2021-09-02RetsevmoSelpercatinibNot proven
- 2021-09-02RetsevmoSelpercatinibNot proven
- 2021-02-18RozlytrekEntrectinibNot proven
- 2020-04-02VitrakviLarotrectinibNot proven
- 2019-08-15LenvimaLenvatinibNot proven
- 2017-07-06CaprelsaVandetanibNon-quantifiable
Data status: 2026-10-29